Estrella Immunopharma Inc.
ESLA
We are a clinical-stage biopharmaceutical company developing T-cell therapies to address treatment challenges for patients with cancers and autoimmune diseases. Our strategy is to harness the evolutionary power of the human immune system to provide patients with potentially safer, more efficacious T-cell therapies compared to traditional CAR-T therapies.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$13M
Op. Margin
–
ROIC
–
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$9M
Net Debt
-$100K
Net Cash Position
Cash & Equiv.
$100K
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with ESLA
Estrella Immunopharma (ESLA) in two numbers
Questions about Estrella Immunopharma
Does Estrella Immunopharma (ESLA) pay a dividend?
No. Estrella Immunopharma (ESLA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Over the last twelve months it returned cash through share buybacks instead, equal to a 0.2% buyback yield. The Dividends tab shows its cash returns.
Source: 10-Q filed 11 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in ESLA's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ESLA
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.